$AMLX
Amylyx Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122833 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $416.0K
YoY Change -99.59%
Cost Of Revenue $809.0K
YoY Change -84.5%
Gross Profit -$393.0K
YoY Change -100.4%
Gross Profit Margin -94.47%
Selling, General & Admin $17.83M
YoY Change -63.41%
% of Gross Profit
Research & Development $21.24M
YoY Change -29.3%
% of Gross Profit
Depreciation & Amortization $221.0K
YoY Change -26.33%
% of Gross Profit
Operating Expenses $39.07M
YoY Change -50.4%
Operating Profit -$75.66M
YoY Change -504.17%
Interest Expense $3.098M
YoY Change -26.24%
% of Operating Profit
Other Income/Expense, Net $2.957M
YoY Change -19.89%
Pretax Income -$72.70M
YoY Change -424.41%
Income Tax
% Of Pretax Income
Net Earnings -$72.70M
YoY Change -447.98%
Net Earnings / Revenue -17476.92%
Basic Earnings Per Share -$1.07
Diluted Earnings Per Share -$1.07
COMMON SHARES
Basic Shares Outstanding 68.55M 68.08M
Diluted Shares Outstanding 68.09M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $234.4M
YoY Change -33.97%
Cash & Equivalents $71.84M
Short-Term Investments $162.6M
Other Short-Term Assets $9.137M
YoY Change -47.18%
Inventory $0.00
Prepaid Expenses
Receivables $1.731M
Other Receivables $0.00
Total Short-Term Assets $245.3M
YoY Change -43.5%
LONG-TERM ASSETS
Property, Plant & Equipment $1.252M
YoY Change -54.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $482.0K
YoY Change 1.26%
Total Long-Term Assets $5.450M
YoY Change -83.22%
TOTAL ASSETS
Total Short-Term Assets $245.3M
Total Long-Term Assets $5.450M
Total Assets $250.7M
YoY Change -46.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.487M
YoY Change -76.66%
Accrued Expenses $50.46M
YoY Change 36.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.92M
YoY Change 18.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $595.0K
YoY Change -77.12%
Total Long-Term Liabilities $595.0K
YoY Change -77.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.92M
Total Long-Term Liabilities $595.0K
Total Liabilities $54.51M
YoY Change 13.13%
SHAREHOLDERS EQUITY
Retained Earnings -$569.1M
YoY Change 83.79%
Common Stock $764.7M
YoY Change 5.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $196.2M
YoY Change
Total Liabilities & Shareholders Equity $250.7M
YoY Change -46.27%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$72.70M
YoY Change -447.98%
Depreciation, Depletion And Amortization $221.0K
YoY Change -26.33%
Cash From Operating Activities -$41.57M
YoY Change 704.06%
INVESTING ACTIVITIES
Capital Expenditures $36.18M
YoY Change 9951.11%
Acquisitions
YoY Change
Other Investing Activities $75.00M
YoY Change -169.62%
Cash From Investing Activities $38.82M
YoY Change -135.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 80.00K
YoY Change -91.01%
NET CHANGE
Cash From Operating Activities -41.57M
Cash From Investing Activities 38.82M
Cash From Financing Activities 80.00K
Net Change In Cash -2.674M
YoY Change -97.62%
FREE CASH FLOW
Cash From Operating Activities -$41.57M
Capital Expenditures $36.18M
Free Cash Flow -$77.75M
YoY Change 1306.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001658551
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41199
dei Entity Registrant Name
EntityRegistrantName
Amylyx Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4600503
dei Entity Address Address Line1
EntityAddressAddressLine1
43 Thorndike St.
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
682-0917
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
AMLX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68547860
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71839000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
170201000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
162556000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
201161000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1731000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40050000
CY2023Q4 us-gaap Inventory Net
InventoryNet
38323000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9137000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14931000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
245263000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
464666000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1252000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2686000
CY2024Q3 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1441000
CY2023Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
719000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2275000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3725000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
44957000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
482000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
701000
CY2024Q3 us-gaap Assets
Assets
250713000
CY2023Q4 us-gaap Assets
Assets
517454000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1487000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22061000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50456000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
57724000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1972000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2257000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
53915000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82042000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
595000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1980000
CY2024Q3 us-gaap Liabilities
Liabilities
54510000
CY2023Q4 us-gaap Liabilities
Liabilities
84022000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68545508
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68545508
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67707432
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67707432
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
764701000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
738177000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-569146000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-304949000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
641000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
197000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
196203000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
433432000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
250713000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
517454000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
416000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102693000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
88036000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
272337000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5218000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5953000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16081000
CY2024Q3 amlx Cost Of Sales Inventory Impairment And Loss On Firm Purchase Commitments
CostOfSalesInventoryImpairmentAndLossOnFirmPurchaseCommitments
809000
amlx Cost Of Sales Inventory Impairment And Loss On Firm Purchase Commitments
CostOfSalesInventoryImpairmentAndLossOnFirmPurchaseCommitments
118680000
CY2024Q3 amlx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
36203000
amlx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
36203000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21237000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30037000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81192000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83273000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17828000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48718000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
97234000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
136115000
us-gaap Restructuring Charges
RestructuringCharges
22851000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
76077000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
83973000
us-gaap Costs And Expenses
CostsAndExpenses
362113000
us-gaap Costs And Expenses
CostsAndExpenses
235469000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-75661000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
18720000
us-gaap Operating Income Loss
OperatingIncomeLoss
-274077000
us-gaap Operating Income Loss
OperatingIncomeLoss
36868000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3098000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4179000
us-gaap Investment Income Interest
InvestmentIncomeInterest
11493000
us-gaap Investment Income Interest
InvestmentIncomeInterest
11784000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-141000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-488000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1371000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-831000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2957000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3691000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10122000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10953000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72704000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
22411000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-263955000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
47821000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1518000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
242000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3281000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-72704000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
20893000
us-gaap Net Income Loss
NetIncomeLoss
-264197000
us-gaap Net Income Loss
NetIncomeLoss
44540000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.66
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.3
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68091446
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67414669
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67990613
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67124407
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68091446
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69748547
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67990613
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70143659
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-72704000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
20893000
us-gaap Net Income Loss
NetIncomeLoss
-264197000
us-gaap Net Income Loss
NetIncomeLoss
44540000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
301000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-138000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
100000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-78000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
437000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
59000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
344000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
13000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
738000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-79000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
444000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-65000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71966000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20814000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-263753000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
44475000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
433432000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
147000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9924000
CY2024Q1 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
-274000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-118793000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
324436000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9570000
CY2024Q2 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
-20000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-72700000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
261309000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6803000
CY2024Q3 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
738000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-72704000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
196203000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
340607000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2777000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7580000
CY2023Q1 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
111000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1573000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
352648000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1687000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10053000
CY2023Q2 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
-97000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
22074000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
386365000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
938000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10283000
CY2023Q3 us-gaap Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
-79000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
20893000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
418400000
us-gaap Profit Loss
ProfitLoss
-264197000
us-gaap Profit Loss
ProfitLoss
44540000
us-gaap Share Based Compensation
ShareBasedCompensation
26297000
us-gaap Share Based Compensation
ShareBasedCompensation
27627000
us-gaap Depreciation
Depreciation
744000
us-gaap Depreciation
Depreciation
787000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8065000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7368000
amlx Cost Of Sales Inventory Impairment And Loss On Firm Purchase Commitments
CostOfSalesInventoryImpairmentAndLossOnFirmPurchaseCommitments
118680000
amlx In Process Research And Development Purchase Expense
InProcessResearchAndDevelopmentPurchaseExpense
36203000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-827000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-38319000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14047000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9253000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
46648000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-303000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-370000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5496000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7596000
amlx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
1450000
amlx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
1335000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-216000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-20574000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
62000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-33415000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
825000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1670000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1509000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108639000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1632000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
137000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
885000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
36203000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
231986000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
174187000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
279000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
246200000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10674000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
71128000
amlx Follow On Offering Costs Paid
FollowOnOfferingCostsPaid
136000
amlx Proceeds From Exercise Of Stock Options And Restricted Stock Units Vesting
ProceedsFromExerciseOfStockOptionsAndRestrictedStockUnitsVesting
1984000
amlx Proceeds From Exercise Of Stock Options And Restricted Stock Units Vesting
ProceedsFromExerciseOfStockOptionsAndRestrictedStockUnitsVesting
6647000
amlx Withholding Taxes Paid On Stock Based Awards
WithholdingTaxesPaidOnStockBasedAwards
1746000
amlx Withholding Taxes Paid On Stock Based Awards
WithholdingTaxesPaidOnStockBasedAwards
3198000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
238000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3313000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-77000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-97640000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
72732000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
170920000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63245000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73280000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
135977000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71839000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135258000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1441000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
719000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73280000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135977000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
344000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
13000
amlx Taxes Withheld On Stock Based Awards Included In Accrued Expenses
TaxesWithheldOnStockBasedAwardsIncludedInAccruedExpenses
54000
amlx Taxes Withheld On Stock Based Awards Included In Accrued Expenses
TaxesWithheldOnStockBasedAwardsIncludedInAccruedExpenses
15000
amlx Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
150000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-264000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-4978000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of the Business</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amylyx Pharmaceuticals, Inc., together with its wholly owned subsidiaries, known as Amylyx or the Company, is a biotechnology company that is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal neurodegenerative diseases and endocrine conditions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 9, 2024, Amylyx completed the acquisition of avexitide for the potential treatment of hyperinsulinemic hypoglycemia, a disease of the endocrine system. Avexitide is an investigational, first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia, or PBH, and has also been studied in congenital hyperinsulinism, or HI, two indications characterized by hyperinsulinemic hypoglycemia. The U.S. Food and Drug Administration, or FDA, has granted avexitide breakthrough therapy designation for both indications, rare pediatric disease designation in congenital HI, and orphan drug designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Amylyx expects to begin the Phase 3 program for avexitide in PBH in the first quarter of 2025.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is also investigating AMX0035, developed by Amylyx, in both neurodegenerative and endocrine diseases where endoplasmic reticulum, or ER, stress and mitochondrial dysfunction are implicated, including progressive supranuclear palsy, or PSP, and Wolfram syndrome. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reported positive topline results from the Phase 2 open-label HELIOS clinical trial in 12 adults living with Wolfram syndrome in October 2024. The Company is engaging with stakeholders, including the FDA, to inform a Phase 3 program and expects to provide an update in 2025. The Company dosed the first participant in the ORION trial, a Phase 2b/3 global clinical trial of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AMX0035 for the treatment of PSP, in December 2023. Data from an interim analysis of the ORION are expected in mid-2025. The Company is also advancing additional drug candidates developed by Amylyx for neurodegenerative diseases including AMX0114, a potent antisense oligonucleotide targeting inhibition of Calpain-2, a key contributor to the axonal (also known as Wallerian) degeneration pathway. The Company received clearance from Health Canada for its Clinical Trial Application for AMX0114 in people living with amyotrophic lateral sclerosis, or ALS, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and plans to begin a Phase 1 multiple ascending dose, placebo-controlled trial called LUMINA in Canada by the end of 2024 or in early 2025.</span></span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2024, the Company announced that it had started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO and ALBRIOZA (AMX0035) for ALS and remove the product from the market based on topline results from the global Phase 3 PHOENIX trial, which did not meet its prespecified primary and secondary endpoints. Amylyx wound down the Open Label Extension as planned. The Company will continue to share learnings from PHOENIX to help inform future ALS research.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, the outcome of preclinical studies and clinical trials, potential difficulties with or delays in timing with respect to regulatory approval processes, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, ability to secure additional capital to fund operations, and risks associated with the economic challenges caused by economic uncertainty in various global markets caused by geopolitical instability and conflict. The Company and its contractors may experience disruptions in supply of items that are essential for its research and development activities, including, for example, raw materials and bulk drug substances that the Company imports from Europe and Canada used in the manufacturing of AMX0035, avexitide and any additional or future product candidates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
amlx Participants Dose Description
ParticipantsDoseDescription
The Company reported positive topline results from the Phase 2 open-label HELIOS clinical trial in 12 adults living with Wolfram syndrome in October 2024. The Company is engaging with stakeholders, including the FDA, to inform a Phase 3 program and expects to provide an update in 2025. The Company dosed the first participant in the ORION trial, a Phase 2b/3 global clinical trial of AMX0035 for the treatment of PSP, in December 2023. Data from an interim analysis of the ORION are expected in mid-2025. The Company is also advancing additional drug candidates developed by Amylyx for neurodegenerative diseases including AMX0114, a potent antisense oligonucleotide targeting inhibition of Calpain-2, a key contributor to the axonal (also known as Wallerian) degeneration pathway. The Company received clearance from Health Canada for its Clinical Trial Application for AMX0114 in people living with amyotrophic lateral sclerosis, or ALS, and plans to begin a Phase 1 multiple ascending dose, placebo-controlled trial called LUMINA in Canada by the end of 2024 or in early 2025.
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates</span>
CY2024Q3 amlx Revenue From Product Sales
RevenueFromProductSales
0
CY2023Q3 amlx Revenue From Contract With Customer Excluding Assessed Tax Gross
RevenueFromContractWithCustomerExcludingAssessedTaxGross
111864000
amlx Revenue From Contract With Customer Excluding Assessed Tax Gross
RevenueFromContractWithCustomerExcludingAssessedTaxGross
114265000
amlx Revenue From Contract With Customer Excluding Assessed Tax Gross
RevenueFromContractWithCustomerExcludingAssessedTaxGross
304822000
CY2024Q3 amlx Gross To Net Adjustments
GrossToNetAdjustments
-416000
CY2023Q3 amlx Gross To Net Adjustments
GrossToNetAdjustments
9171000
amlx Gross To Net Adjustments
GrossToNetAdjustments
26229000
amlx Gross To Net Adjustments
GrossToNetAdjustments
32485000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
416000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
102693000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
88036000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
272337000
CY2023Q4 amlx Gross To Net Adjustments Reserve
GrossToNetAdjustmentsReserve
19162000
amlx Gross To Net Adjustments Reserve Provision Related To Current Period Sales
GrossToNetAdjustmentsReserveProvisionRelatedToCurrentPeriodSales
29403000
amlx Gross To Net Adjustments Reserve Adjustments Related To Prior Period Sales
GrossToNetAdjustmentsReserveAdjustmentsRelatedToPriorPeriodSales
-3174000
amlx Gross To Net Adjustments Reserve Credits And Payments Made
GrossToNetAdjustmentsReserveCreditsAndPaymentsMade
-26068000
CY2024Q3 amlx Gross To Net Adjustments Reserve
GrossToNetAdjustmentsReserve
19323000
CY2022Q4 amlx Gross To Net Adjustments Reserve
GrossToNetAdjustmentsReserve
4304000
amlx Gross To Net Adjustments Reserve Provision Related To Current Period Sales
GrossToNetAdjustmentsReserveProvisionRelatedToCurrentPeriodSales
33001000
amlx Gross To Net Adjustments Reserve Adjustments Related To Prior Period Sales
GrossToNetAdjustmentsReserveAdjustmentsRelatedToPriorPeriodSales
-516000
amlx Gross To Net Adjustments Reserve Credits And Payments Made
GrossToNetAdjustmentsReserveCreditsAndPaymentsMade
-26740000
CY2023Q3 amlx Gross To Net Adjustments Reserve
GrossToNetAdjustmentsReserve
10049000
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
53144000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
18945000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11191000
CY2023Q4 amlx Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
83280000
us-gaap Inventory Write Down
InventoryWriteDown
92500000
CY2024Q3 amlx Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
4399000
CY2023Q4 amlx Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
12625000
CY2024Q3 amlx Accrued Benefits And Incentive Compensation
AccruedBenefitsAndIncentiveCompensation
7962000
CY2023Q4 amlx Accrued Benefits And Incentive Compensation
AccruedBenefitsAndIncentiveCompensation
16790000
CY2024Q3 amlx Accrued Manufacturing
AccruedManufacturing
4008000
CY2023Q4 amlx Accrued Manufacturing
AccruedManufacturing
1652000
CY2024Q3 amlx Accrued Consulting And Other Professional Fess
AccruedConsultingAndOtherProfessionalFess
1944000
CY2023Q4 amlx Accrued Consulting And Other Professional Fess
AccruedConsultingAndOtherProfessionalFess
6506000
CY2024Q3 amlx Rebates And Other Gross To Net Adjustments
RebatesAndOtherGrossToNetAdjustments
18834000
CY2023Q4 amlx Rebates And Other Gross To Net Adjustments
RebatesAndOtherGrossToNetAdjustments
16063000
CY2023Q4 amlx Royalty Payable
RoyaltyPayable
3111000
CY2024Q3 amlx Loss On Future Purchase Commitments
LossOnFuturePurchaseCommitments
12743000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
566000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
977000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
50456000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
57724000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9823248
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.39
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27639000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3056911
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.56
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
146398
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
780000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4390010
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.47
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8343751
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2576000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3864567
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
579000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4479184
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
13.59
amlx Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm
P8Y9M18D
CY2024Q3 amlx Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue
1996000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
18400000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
28200000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
24800000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6803000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10176000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26297000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27627000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-72704000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
20893000
us-gaap Net Income Loss
NetIncomeLoss
-264197000
us-gaap Net Income Loss
NetIncomeLoss
44540000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68091446
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67414669
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67990613
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67124407
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2333878
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3019252
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68091446
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69748547
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67990613
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70143659
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.66
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.3
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10611485
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6597562
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10611485
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6447549
CY2024Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
36200000
CY2024Q3 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
35100000
CY2024Q3 us-gaap Asset Acquisition Consideration Transferred Transaction Cost
AssetAcquisitionConsiderationTransferredTransactionCost
1100000
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
0
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1400000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
700000
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
27200000
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On September 12, 2024, the Company entered into a new office lease in Cambridge, Massachusetts for office space for its headquarters facility. The lease provides office space of approximately 15,267 square feet and for base monthly rent payments beginning at $0.1 million that increase annually by approximately 2.5% over the term of five years from the date of occupancy.
CY2024Q3 amlx Area Of Lease Property
AreaOfLeaseProperty
15267
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2024Q3 amlx Annual Increase Percentage Of Rent Payments
AnnualIncreasePercentageOfRentPayments
0.025
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2024Q3 amlx Lease Commencement Date Expected
LeaseCommencementDateExpected
2025-06-01
us-gaap Severance Costs1
SeveranceCosts1
21812000
amlx Contract Termination Costs Impairment Of Assets And Other Costs
ContractTerminationCostsImpairmentOfAssetsAndOtherCosts
1039000
us-gaap Restructuring Costs
RestructuringCosts
22851000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-122833-index-headers.html Edgar Link pending
0000950170-24-122833-index.html Edgar Link pending
0000950170-24-122833.txt Edgar Link pending
0000950170-24-122833-xbrl.zip Edgar Link pending
amlx-20240930.htm Edgar Link pending
amlx-20240930.xsd Edgar Link pending
amlx-ex31_1.htm Edgar Link pending
amlx-ex31_2.htm Edgar Link pending
amlx-ex31_3.htm Edgar Link pending
amlx-ex32_1.htm Edgar Link pending
amlx-ex32_2.htm Edgar Link pending
amlx-ex32_3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
amlx-20240930_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable